SubHero Banner

Epclusa® (sofosbuvir/velpatasvir) – Expanded indication, new formulation approval

June 10, 2021 - Gilead announced the FDA approval of Epclusa (sofosbuvir/velpatasvir), for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis and with decompensated cirrhosis for use in combination with ribavirin.

Download PDF